X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE IPCA LABS TTK HEALTHCARE/
IPCA LABS
 
P/E (TTM) x 18.9 30.8 61.4% View Chart
P/BV x 2.2 4.5 48.9% View Chart
Dividend Yield % 0.8 0.1 725.9%  

Financials

 TTK HEALTHCARE   IPCA LABS
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-18
IPCA LABS
Mar-18
TTK HEALTHCARE/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,458695 209.6%   
Low Rs795400 198.8%   
Sales per share (Unadj.) Rs408.7260.2 157.1%  
Earnings per share (Unadj.) Rs12.919.0 67.8%  
Cash flow per share (Unadj.) Rs23.633.1 71.5%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %0.40.2 243.1%  
Book value per share (Unadj.) Rs164.9213.0 77.4%  
Shares outstanding (eoy) m14.13126.20 11.2%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.82.1 130.9%   
Avg P/E ratio x87.628.9 303.4%  
P/CF ratio (eoy) x47.616.6 287.5%  
Price / Book Value ratio x6.82.6 265.7%  
Dividend payout %38.95.3 737.7%   
Avg Mkt Cap Rs m15,91669,120 23.0%   
No. of employees `0002.213.3 16.9%   
Total wages/salary Rs m1,0907,359 14.8%   
Avg. sales/employee Rs Th2,573.82,477.4 103.9%   
Avg. wages/employee Rs Th485.7555.2 87.5%   
Avg. net profit/employee Rs Th81.0180.6 44.8%   
INCOME DATA
Net Sales Rs m5,77632,836 17.6%  
Other income Rs m76418 18.1%   
Total revenues Rs m5,85133,254 17.6%   
Gross profit Rs m4264,505 9.4%  
Depreciation Rs m1521,777 8.6%   
Interest Rs m47240 19.7%   
Profit before tax Rs m3022,905 10.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m120511 23.4%   
Profit after tax Rs m1822,394 7.6%  
Gross profit margin %7.413.7 53.7%  
Effective tax rate %39.717.6 225.9%   
Net profit margin %3.17.3 43.1%  
BALANCE SHEET DATA
Current assets Rs m2,55619,455 13.1%   
Current liabilities Rs m1,67510,076 16.6%   
Net working cap to sales %15.328.6 53.4%  
Current ratio x1.51.9 79.0%  
Inventory Days Days3398 34.2%  
Debtors Days Days3567 52.2%  
Net fixed assets Rs m1,10320,260 5.4%   
Share capital Rs m141252 56.0%   
"Free" reserves Rs m2,18826,633 8.2%   
Net worth Rs m2,33026,886 8.7%   
Long term debt Rs m72,340 0.3%   
Total assets Rs m4,07341,173 9.9%  
Interest coverage x7.413.1 56.3%   
Debt to equity ratio x00.1 3.3%  
Sales to assets ratio x1.40.8 177.8%   
Return on assets %5.66.4 87.9%  
Return on equity %7.88.9 87.6%  
Return on capital %14.910.8 138.7%  
Exports to sales %3.047.6 6.3%   
Imports to sales %0.614.9 4.0%   
Exports (fob) Rs m17215,642 1.1%   
Imports (cif) Rs m354,884 0.7%   
Fx inflow Rs m17215,642 1.1%   
Fx outflow Rs m554,884 1.1%   
Net fx Rs m11710,759 1.1%   
CASH FLOW
From Operations Rs m2533,411 7.4%  
From Investments Rs m-226-1,354 16.7%  
From Financial Activity Rs m-72-1,304 5.5%  
Net Cashflow Rs m-41753 -5.5%  

Share Holding

Indian Promoters % 65.4 45.9 142.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 11.4 32.5%  
FIIs % 5.2 25.3 20.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.8 17.4 148.3%  
Shareholders   12,723 36,892 34.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   ORCHID PHARMA LTD  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare TTK HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 490 Points Higher; Oil & Gas and Telecom Stocks Witness Buying(Closing)

Indian share markets continued to witness buying interest and ended their trading session on a positive note. Gains were largely seen in the oil & gas sector.

Related Views on News

TTK HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 60.1% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, TTK HEALTHCARE has posted a net profit of Rs 49 m (down 60.1% YoY). Sales on the other hand came in at Rs 1 bn (up 2.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 15.3% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, TTK HEALTHCARE has posted a net profit of Rs 67 m (down 15.3% YoY). Sales on the other hand came in at Rs 2 bn (up 16.3% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Apr 24, 2019 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE - ASTRAZENECA PHARMA COMPARISON

COMPARE TTK HEALTHCARE WITH

MARKET STATS